Citius Oncology (CTOR) Operating Expenses (2022 - 2026)

Citius Oncology (CTOR) has reported Operating Expenses for 5 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 96.54% year-over-year to $9.7 million in Q2 2026; TTM through Jun 2026 was $52.8 million, a 61.36% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 14.34% from the prior year.
• Operating Expenses was $9.7 million for Q2 2026 at Citius Oncology, down from $30.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $30.0 million in Q1 2026 and troughed at $21666.0 in Q4 2022.
• A 5-year average of $7.2 million and a median of $5.7 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 21054.82% in 2023 and slumped 64.43% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $21666.0 in 2022, then jumped by 21054.82% to $4.6 million in 2023, then soared by 39.52% to $6.4 million in 2024, then jumped by 31.47% to $8.4 million in 2025, then rose by 15.6% to $9.7 million in 2026.
• The last three Operating Expenses figures came in at $9.7 million (Q2 2026), $30.0 million (Q1 2026), and $8.4 million (Q4 2025), per Business Quant data.